You are here: Industry Insights > M&A

News List

Bristol-Myers Squibb hands Upsa consumer biz to Taisho for $1.6B fiercepharma
December 20, 2018
When it rains, it pours. Just as Pfizer and GlaxoSmithKline teamed up on an industry-leading consumer health joint venture, Bristol-Myers Squibb struck its own deal in the sector.
Long-awaited M&A boom will hit biopharma in 2019 despite persistent worries, prognosticators predict fiercepharma
December 20, 2018
When Congress passed a business-friendly tax package last year, pharma prognosticators predicted 2018 would be the year that mergers and acquisitions in the sector would finally gain steam. They were wrong.
Tesaro's deal struggles? They're actually a good omen for Clovis: analyst fiercepharma
December 20, 2018
PARP drugmaker Tesaro may have had a tough time finding a buyer in GlaxoSmithKline. But that doesn’t mean rival Clovis won’t be able to land its own, one analyst says.
Thorny path: A replay of how Tesaro got its $5.1B GlaxoSmithKline buyout fiercepharma
December 19, 2018
With its Tesaro buyout, GlaxoSmithKline CEO Emma Walmsley finally beefed up in oncology, one of the fields she tagged for growth about a year ago. For the small biotech, the sale marked the end of a longer and more arduous journey.
Bristol-Myers Squibb nears $1.6B sale of OTC unit Upsa to Taisho: report fiercepharma
December 19, 2018
Amid an industrywide shift away from the sector, Bristol-Myers Squibb is close to becoming the latest Big Pharma to exit consumer health. And word is Japan’s Taisho will be the one to help the company do it.
Bausch Health inks $200M ‘stalking horse’ deal for bankrupt Trulance maker Synergy fiercepharma
December 14, 2018
Could a still-recovering company buying a distressed one create a better business? Bausch Health apparently thinks so when it comes to Synergy Pharma, as it's agreed to pay $200 million for the now-bankrupt maker of Trulance.
Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger fiercepharma
December 11, 2018
Akorn once again tried and failed to salvage its $4.3 billion merger with Fresenius. Delaware's top court ruled that Fresenius had nixed the deal legally after data problems cropped up, and in the wake of the decision, Akorn's CEO made his exit.
Activist investor Elliott's latest target? A 2-way split at struggling Bayer: report fiercepharma
December 11, 2018
Think again. Armed with a stake in the German conglomerate, activist investor Elliott Management is reportedly pushing for a two-way split.
GlaxoSmithKline taps Unilever as lead bidder in Indian Horlicks buyout: report fiercepharma
December 06, 2018
GlaxoSmithKline has been working to unload its Indian consumer products business, including the nutritional beverage Horlicks, and now the company may be almost there.
Takeda ex-chairman speaks out against Shire buy a week before key votes fiercepharma
December 06, 2018
Just a week ahead of the final shareholder votes on Takeda’s $62 billion acquisition of Shire, a former Takeda chairman and the last member of the founding family to have run the Japanese pharma has come forward against the deal.

Previous page 1 2 3 4 5 6 Next page